These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28082435)

  • 1. Cumulated Activity Comparison of
    Laffon E; Thumerel M; Jougon J; Marthan R
    J Nucl Med; 2017 Jun; 58(6):888-890. PubMed ID: 28082435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
    J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
    Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z
    J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
    Niu G; Li Z; Xie J; Le QT; Chen X
    J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
    Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer.
    Heidari P; Esfahani SA; Turker NS; Wong G; Wang TC; Rustgi AK; Mahmood U
    J Nucl Med; 2015 Aug; 56(8):1246-51. PubMed ID: 26069303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
    BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
    Miao Z; Ren G; Liu H; Jiang L; Cheng Z
    Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.
    Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ
    J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
    Cai W; Chen K; He L; Cao Q; Koong A; Chen X
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.